DNA Diagnostics Market - Global Outlook & Forecast 2025-2030
THE GLOBAL DNA DIAGNOSTICS MARKET SIZE IS EXPECTED TO REACH USD 21.69 BILLION BY 2030 FROM USD 13.07 BILLION IN 2024, GROWING AT A CAGR OF 8.81% DURING THE FORECAST PERIOD.
THE GLOBAL DNA DIAGNOSTICS MARKET SIZE IS EXPECTED TO REACH USD 21.69 BILLION BY 2030 FROM USD 13.07 BILLION IN 2024, GROWING AT A CAGR OF 8.81% DURING THE FORECAST PERIOD.
The DNA Diagnostics Market Size, Share, & Trends Analysis Report By
- Product Type: Consumables, Instruments & Software, and Services
- Technology: Polymerase Chain Reaction (PCR), Sequencing, In-Situ Hybridization (ISH), Microarray, DNA Fingerprinting, and Others
- Sample Type: Blood, Serum & Plasma, Saliva, and Others
- Application: Cancer, Infectious Diseases, Prenatal Testing, Newborn Genetic Screening, Forensics, and Others
- End-User: Diagnostic Centers, Hospitals & Clinics, and Others
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030.
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
DNA DIAGNOSTICS MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2030) | USD 21.69 Billion |
| Market Size (2024) | USD 13.07 Billion |
| CAGR (2024-2030) | 8.81% |
| HISTORIC YEAR | 2021-2023 |
| BASE YEAR | 2024 |
| FORECAST YEAR | 2025-2030 |
| SEGMENTS BY | Product Type, Technology, Sample Type, Application, End-User, and Geography |
| GEOGRAPHIC ANALYSIS | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY PLAYERS | Abbott, F. Hoffmann La-Roche, Illumina, QIAGEN, and Thermo Fisher Scientific |
MARKET OUTLOOK
The global DNA diagnostics market size was valued at USD 13.07 billion in 2024 and is expected to reach USD 21.69 billion by 2030, growing at a CAGR of 8.81% during the forecast period. The market is growing rapidly due to the progression of molecular biology, increased demand for personalized medicine, and increased prevalence of genetic diseases, infectious diseases, and cancer. DNA diagnostics is a critical part of modern health care as it includes the detection of mutations and the analysis of individuals' genetic material for hereditary diseases and susceptibility to diseases. The market includes a variety of technologies, including polymerase chain reaction (PCR), next-generation (NGS) sequencing, and microarrays, allowing for accurate and efficient genetic testing.
Key factors in the global DNA diagnostics market include increasing awareness of genetic diseases, a growing aging population, and the expansion of precision medicine. Furthermore, the widespread adoption of non-invasive prenatal testing (NIPT), pharmacogenomics, and oncology diagnosis is further growing in the market. Furthermore, North America dominates the global market with advanced health infrastructure, strong R&D investments, and regulatory support for genetic testing. However, APAC is a lucrative market due to increased health spending, government initiatives in genomic research, and increased access to DNA testing services. Furthermore, the integration of artificial intelligence (AI) and bioinformatics into DNA diagnostics improves data analysis and interpretation, leading to faster and more accurate diagnoses.
Despite its growth, the DNA diagnostics market faces challenges such as high costs of DNA testing, ethical concerns regarding the protection of genetic data, and complex regulatory frameworks in various regions. However, increasing support for ongoing technological innovation and government support for genomic research is expected to overcome these challenges and drive market expansion. Overall, the global DNA diagnostics market is poised for significant growth, transforming the landscape of disease detection, treatment, and prevention. As genetic testing becomes more accessible and integrated into routine healthcare, the market will continue to play a pivotal role in shaping the future of precision medicine and personalized healthcare.
MARKET TRENDS & DRIVERS
Emergence of Liquid Biopsy
The development of liquid biopsy is an innovative jump in DNA diagnostics. By activating non-invasive, accurate, real-time analysis of genetic material, liquid biopsies open new limitations to the detection of disease, personalized medicine, and treatment surveillance. With the continued advances and growth of various applications, this technology is posing an unprecedented opportunity for growth and innovation in the global DNA diagnostics market.
Increase in Direct-to-Consumer (DTC) Testing
The increase in DTC testing is revolutionizing the global DNA diagnostics market by making genetic insights more accessible and personalized. Rising consumer interest in ancestry and health-related insights is driving this trend, offering significant growth opportunities for companies. As technological advancements and strategic partnerships continue to shape the industry, the future of DNA diagnostics lies in innovation, personalization, and ethical practices.
Transition from Classical to Smart Bioinformatics
The transition from classical to smart bioinformatics, coupled with the rising integration of AI, is reshaping the global DNA diagnostics market. This paradigm shift enhances the accuracy, speed, and accessibility of genetic testing, unlocking immense potential for innovation in personalized medicine, cancer diagnostics, and infectious disease management. By embracing these advancements, the global DNA diagnostics market is poised for sustained growth, addressing the evolving healthcare needs of a diverse global population.
Advancements in Genomics and Personalized Medicine
Advancements in genomics and personalized medicine are reshaping the global DNA diagnostics market, driving innovation, and creating new opportunities for healthcare providers, technology developers, and patients. By leveraging these advancements, the market is positioned to address critical healthcare challenges and improve patient outcomes, heralding a new age of precision diagnostics and treatment.
Increasing Prevalence of Genetic and Chronic Disorders
The increasing prevalence of genetic and chronic disorders has emerged as a key driver of the global DNA diagnostics market. Advances in molecular technologies, the growing adoption of precision medicine, and supportive government initiatives have created a robust foundation for the market’s expansion. The future of DNA diagnostics holds immense potential for transforming healthcare, offering innovative solutions for early diagnosis, personalized treatment, and improved patient outcomes. As the market continues to evolve, it will play a pivotal role in addressing the global healthcare burden of genetic and chronic diseases.
Technological Advancements in DNA Sequencing
Technological advancements in DNA sequencing are undeniably the driving force behind the rapid growth of the global DNA diagnostics market. By enabling highly accurate and efficient genetic analysis, these innovations are transforming healthcare delivery and paving the way for personalized medicine. As DNA sequencing technologies continue to evolve, they hold immense potential to reshape diagnostics, improve patient outcomes, and expand the horizons of genomic medicine on a global scale.
Expanding Applications of DNA Diagnostics
The expanding applications of DNA diagnostics across disease detection, personalized medicine, reproductive health, consumer genomics, and drug development are driving the growth of the global DNA diagnostics market. Advances in genomics, combined with technological innovations, are transforming healthcare by making diagnostics more precise, accessible, and impactful. As the scope of DNA diagnostics continues to widen, it will play a pivotal role in shaping the future of medicine and public health.
Rising Awareness of Early Disease Detection
The rising awareness of early disease detection is a crucial factor driving the global DNA diagnostics market. With an increasing emphasis on preventive healthcare, advancements in genetic testing technologies, and the growing need for personalized medicine, DNA diagnostics are becoming indispensable tools for early disease detection. The benefits of early diagnosis, including improved patient outcomes and more efficient healthcare systems, continue to fuel the demand for DNA diagnostics.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT TYPE
The global DNA diagnostics market is segmented based on product type, including consumables, instruments & software, and services. The consumables segment holds the most significant market share in 2024. Consumables are a key factor in the DNA diagnostics market, leading to the success and efficiency of genetic testing technologies. From reagents and PCR consumables to sequencing kits and sample preparation tools, these products are essential to the functioning of diagnostic tests across numerous applications. The increasing demand for genetic testing, personalized medicine, and precision healthcare, combined with advances in genomic technologies, is causing the market for DNA diagnostics consumables. Furthermore, instruments and software are essential to the DNA diagnostics market, enabling innovation and improving patient outcomes through precise and efficient diagnostic procedures. While challenges such as regulatory compliance and cost remain, ongoing advancements in automation, AI, and cloud computing are unlocking new opportunities
INSIGHTS BY TECHNOLOGY
The increasing prevalence of infectious diseases like COVID-19, tuberculosis, and HIV, along with its cost-effectiveness and high sensitivity, continues to drive the adoption of PCR-based DNA diagnostics. Such factors have contributed to the growth of the Polymerase Chain Reaction (PCR) segment in the global DNA diagnostics market, enabling it to hold the most significant segmental share. Advancements in real-time PCR (qPCR) and digital PCR (dPCR) further enhance accuracy and efficiency. The rising demand for Next-Generation Sequencing (NGS) in precision medicine, oncology, and rare disease diagnosis is a major growth driver. The decreasing cost of sequencing and improvements in bioinformatics tools are also expanding its applications in genetic testing.
The growing need for cancer diagnostics and cytogenetic analysis is fueling the demand for ISH techniques, including Fluorescence In Situ Hybridization (FISH), which enables detailed chromosomal analysis for disease detection and prognosis. The expanding applications of microarrays in gene expression profiling, pharmacogenomics, and prenatal screening contribute to market growth. Its high-throughput nature allows for large-scale genetic analysis, making it valuable for clinical and research applications.
INSIGHTS BY SAMPLE TYPE
The global DNA diagnostics market by sample type is segmented into blood, serum & plasma, saliva, and others. Blood, serum, and plasma remain dominant due to their high reliability, especially in oncology and prenatal testing, while saliva-based tests are fueling the growth of at-home and pharmacogenomics markets. In 2024, the blood, serum & plasma segment held the most significant market share. The market for DNA diagnostics using these sample types is growing rapidly, driven by innovations in sequencing, PCR, and automated processing technologies. Future advancements in molecular diagnostics, coupled with improved regulatory frameworks, will further enhance the adoption of these sample types in clinical and research settings. However, alternative sample types like buccal swabs, tissue, urine, and hair are driving specialized applications in cancer, forensic, and genetic screening, ensuring continued expansion of the global DNA diagnostics market. The choice of sample type in DNA diagnostics is influenced by factors such as ease of collection, accuracy, and specific clinical applications.
INSIGHTS BY APPLICATION
The global DNA diagnostics market by application is segmented into cancer, infectious diseases, prenatal testing, newborn genetic screening, forensics, and others. The cancer segment dominated the global market share and is poised for significant growth during the forecast period. DNA diagnostics is transforming cancer care by enabling early detection, guiding targeted therapies, assessing hereditary risk, and monitoring treatment response. Despite challenges such as cost, data interpretation, and ethical concerns, the market is poised for significant growth. Continued advancements in NGS, liquid biopsy, and AI-driven genomic analysis will drive further innovation in cancer diagnostics, ultimately improving patient outcomes worldwide. Furthermore, DNA diagnostics is transforming infectious disease management by providing highly accurate, rapid, and cost-effective molecular testing solutions. As next-generation sequencing, automation, and AI-driven analytics continue to advance, the global DNA diagnostics market will expand further. Companies investing in affordable, rapid, and accessible molecular diagnostics will play a critical role in the future of infectious disease control and global health security.
INSIGHTS BY END-USER
The global DNA diagnostics market by end-user is segmented into diagnostic centers, hospitals & clinics, and others. Diagnostic centers will dominate the global market in 2024, capturing the largest share and driving significant growth in the market. Diagnostic centers are benefiting from technological advancements and outsourcing trends, hospitals & clinics are integrating genomics into personalized medicine, and research institutions, forensic labs, Pharma & biotech companies, CROs & CDMos are expanding applications in drug discovery and forensic science. With continuous innovation, regulatory support, and increasing awareness, DNA diagnostics is set to play a crucial role in the future of healthcare and biotechnology. Each End-user segment is significantly contributing to the growth of the global DNA diagnostics market.
GEOGRAPHICAL ANALYSIS
North America, led by the U.S. and Canada, holds the largest share of the global DNA diagnostics market, driven by the high adoption of genetic testing, precision medicine, and NGS-based diagnostics. The rapid development of next-generation sequencing (NGS), CRISPR-based technologies, and polymerase chain reaction (PCR) has made DNA diagnostics more accurate, faster, and cost-effective. The growth of precision medicine, which tailors medical treatment to individual genetic profiles, has further fueled the demand for genetic testing. Furthermore, the U.S. dominates the global DNA diagnostics market due to the strong presence of leading industry players and government funding for genomics (e.g., NIH’s All of Us Research Program).
Europe is the second-largest DNA diagnostics market, led by Germany, the UK, France, Italy, and Spain. Growth is fueled by strong regulatory support, government-backed genomics programs, and high adoption of molecular diagnostics. The UK’s Genomics England Initiative and Germany’s National Genome Initiative are driving advancements in DNA-based diagnostics. Furthermore, APAC is the fastest-growing region in the global DNA diagnostics market due to rising healthcare investments, growing awareness of genetic diseases, and expanding diagnostic infrastructure. China, Japan, and India are major contributors, with initiatives like national genome projects boosting market growth.
The DNA diagnostics market in Latin America is experiencing significant growth, driven by increasing healthcare needs, advancements in genetic technologies, and rising awareness about the potential of genetic testing in disease diagnosis and prevention. Latin America, with its diverse population and evolving healthcare infrastructure, is emerging as a key region for the adoption of DNA diagnostics. Brazil and Mexico lead the region with expanding healthcare facilities. Further, the Middle East & Africa region is in the early stages of DNA diagnostics adoption, but growth is driven by government initiatives in Gulf countries (UAE, Saudi Arabia) to develop genomic research programs. While the region presents a complex landscape with diverse healthcare systems, varying levels of access to technology, and different regulatory frameworks, the demand for DNA diagnostics services is expected to continue expanding.
COMPETITIVE LANDSCAPE
The global DNA diagnostics market is experiencing rapid growth, driven by advancements in molecular biology, next-generation sequencing (NGS), polymerase chain reaction (PCR) technologies, and bioinformatics. The increasing prevalence of genetic disorders, infectious diseases, and cancers, coupled with the rising adoption of precision medicine, has fueled demand for DNA-based diagnostic solutions. This market is highly competitive, with established biotechnology and life sciences companies striving for technological superiority, cost-effectiveness, and regulatory approvals. The DNA diagnostics market is dominated by global biotechnology and molecular diagnostics companies specializing in genetic sequencing, PCR, microarrays, and companion diagnostics. Furthermore, companies are focusing on clinical genomics, oncology, reproductive health, and infectious diseases to increase the adoption of DNA-based diagnostics. For instance, Illumina’s NGS technology is expanding into cancer diagnostics, prenatal screening, and rare disease detection.
The global DNA diagnostics market is highly competitive, with major players investing in NGS, PCR, liquid biopsy, and AI-driven bioinformatics to maintain leadership. Companies like Abbott, F. Hoffmann-La Roche, Illumina, QAIGEN, and Thermo Fisher Scientific are driving innovation, while emerging players and startups are disrupting traditional models. For instance, Abbott is a major player in molecular diagnostics, focusing on infectious disease testing, oncology, and genetic disorders. The company has strong expertise in real-time PCR, point-of-care (POC) diagnostics, and molecular diagnostic platforms, making DNA testing more accessible and automated.
SNAPSHOT
The global DNA diagnostics market size is expected to grow at a CAGR of approximately 8.81% from 2024 to 2030.
The following factors are likely to contribute to the growth of the DNA diagnostics market during the forecast period:
- Increasing Prevalence of Genetic and Chronic Disorders
- Technological Advancements in DNA Sequencing
- Expanding Applications of DNA Diagnostics
- Rising Awareness of Early Disease Detection
Base Year: 2024
Forecast Year: 2025-2030
The report considers the present scenario of the global DNA diagnostics market and its market dynamics for 2025−2030. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Company Profiles
- Abbott
- Business Overview
- Product Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- F. Hoffmann La-Roche
- Illumina
- QIAGEN
- Thermo Fisher Scientific
Other Prominent Vendors
- 23andMe
- Business Overview
- Product Offerings
- 24Genetics
- Agilent Technologies
- Ancestry
- Beyond Nutrition Health and Wellness Services DMCC
- BillionToOne
- CircleDNA
- Danaher
- EverlyWell
- GE Healthcare
- GeneDx
- Genetrack India
- Helix
- Igenomix
- Mainz Biomed N.V.
- Mapmygenome
- Merck KgaA
- myDNA Life Australia
- MyHeritage
- Natera
- tellmeGen
- Vitagen-X Precision Nutrition
Segmentation by Product Type
- Consumables
- Instruments & Software
- Services
Segmentation by Technology
- Polymerase Chain Reaction (PCR)
- Sequencing
- In-Situ Hybridization (ISH)
- Microarray
- DNA Fingerprinting
- Others
Segmentation by Sample Type
- Blood, Serum & Plasma
- Saliva
- Others
Segmentation by Application
- Cancer
- Infectious Diseases
- Prenatal Testing
- Newborn Genetic Screening
- Forensics
- Others
Segmentation by End-User
- Diagnostic Centers
- Hospitals & Clinics
- Others
Segmentation by Geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- The U.K.
- France
- Italy
- Spain
- Switzerland
- Netherlands
- APAC
- China
- Japan
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
- UAE
Frequently Asked Questions
How big is the global DNA diagnostics market?
What is the growth rate of the global DNA diagnostics market?
Which region dominates the global DNA diagnostics market share?
What are the significant trends in the DNA diagnostics industry?
Who are the key players in the global DNA diagnostics market?
LIST OF EXHIBITS
EXHIBIT 1 MARKET SIZE CALCULATION APPROACH 2024
EXHIBIT 2 GLOBAL DNA DIAGNOSTICS MARKET BY GEOGRAPHY: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 3 GLOBAL DNA DIAGNOSTICS MARKET BY PRODUCT TYPE: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 4 GLOBAL DNA DIAGNOSTICS MARKET BY TECHNOLOGY: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 5 GLOBAL DNA DIAGNOSTICS MARKET BY SAMPLE TYPE: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 6 GLOBAL DNA DIAGNOSTICS MARKET BY APPLICATION: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 7 GLOBAL DNA DIAGNOSTICS MARKET BY END-USER: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 8 IMPACT OF EMERGENCE OF LIQUID BIOPSY
EXHIBIT 9 IMPACT OF INCREASE IN DIRECT-TO-CONSUMER (DTC) TESTING
EXHIBIT 10 IMPACT OF TRANSITION FROM CLASSICAL TO SMART BIOINFORMATICS
EXHIBIT 11 IMPACT OF ADVANCEMENTS IN GENOMICS AND PERSONALIZED MEDICINE
EXHIBIT 12 IMPACT OF INCREASING PREVALENCE OF GENETIC AND CHRONIC DISORDERS
EXHIBIT 13 IMPACT OF TECHNOLOGICAL ADVANCEMENTS IN DNA SEQUENCING
EXHIBIT 14 IMPACT OF EXPANDING APPLICATIONS OF DNA DIAGNOSTICS
EXHIBIT 15 IMPACT OF RISING AWARENESS OF EARLY DISEASE DETECTION
EXHIBIT 16 IMPACT OF AVAILABILITY OF ALTERNATE DISEASE DIAGNOSTIC & DETECTION METHODS
EXHIBIT 17 IMPACT OF ETHICAL AND PRIVACY CONCERNS
EXHIBIT 18 IMPACT OF COMPLEX REGULATORY FRAMEWORKS
EXHIBIT 19 GLOBAL DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 20 FIVE FORCES ANALYSIS 2024
EXHIBIT 21 INCREMENTAL GROWTH BY PRODUCT TYPE 2024 & 2030
EXHIBIT 22 GLOBAL DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 23 GLOBAL DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 24 GLOBAL CONSUMABLES DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 25 GLOBAL CONSUMABLES DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 26 GLOBAL INSTRUMENTS & SOFTWARE DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 27 GLOBAL INSTRUMENTS & SOFTWARE DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 28 GLOBAL SERVICES DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 29 GLOBAL SERVICES DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 30 INCREMENTAL GROWTH BY TECHNOLOGY 2024 & 2030
EXHIBIT 31 GLOBAL DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 32 GLOBAL DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 33 GLOBAL PCR DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 34 GLOBAL PCR DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 35 GLOBAL SEQUENCING DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 36 GLOBAL SEQUENCING DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 37 GLOBAL IN-SITU HYBRIDIZATION DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 38 GLOBAL IN-SITU HYBRIDIZATION DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 39 GLOBAL MICROARRAY DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 40 GLOBAL MICROARRAY DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 41 GLOBAL DNA FINGERPRINTING DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 42 GLOBAL DNA FINGERPRINTING DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 43 GLOBAL OTHER DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 44 GLOBAL OTHER DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 45 INCREMENTAL GROWTH BY SAMPLE TYPE 2024 & 2030
EXHIBIT 46 GLOBAL DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 47 GLOBAL DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 48 GLOBAL BLOOD, SERUM & PLASMA DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 49 GLOBAL BLOOD, SERUM & PLASMA DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 50 GLOBAL SALIVA DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 51 GLOBAL SALIVA DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 52 GLOBAL OTHER DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 53 GLOBAL OTHER DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 54 INCREMENTAL GROWTH BY APPLICATION 2024 & 2030
EXHIBIT 55 GLOBAL DNA DIAGNOSTICS MARKET BY APPLICATION 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 56 GLOBAL DNA DIAGNOSTICS MARKET BY APPLICATION 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 57 GLOBAL CANCER DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 58 GLOBAL CANCER DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 59 GLOBAL INFECTIOUS DISEASES DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 60 GLOBAL INFECTIOUS DISEASES DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 61 GLOBAL PRENATAL TESTING DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 62 GLOBAL PRENATAL TESTING DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 63 GLOBAL FORENSICS DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 GLOBAL FORENSICS DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 65 GLOBAL NEWBORN GENETIC SCREENING DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL NEWBORN GENETIC SCREENING DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 67 GLOBAL OTHER DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 68 GLOBAL OTHER DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 69 INCREMENTAL GROWTH BY END USER 2024 & 2030
EXHIBIT 70 GLOBAL DNA DIAGNOSTICS MARKET BY END USER 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 71 GLOBAL DNA DIAGNOSTICS MARKET BY END USER 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 72 GLOBAL DIAGNOSTIC CENTERS DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 GLOBAL DIAGNOSTIC CENTERS DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 74 GLOBAL HOSPITALS DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 75 GLOBAL HOSPITALS & CLINICS DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 76 GLOBAL OTHER DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 77 GLOBAL OTHER DNA DIAGNOSTICS MARKET 2021-2030 ($ BILLION)
EXHIBIT 78 INCREMENTAL GROWTH BY GEOGRAPHY 2024 & 2030
EXHIBIT 79 GLOBAL DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 80 GLOBAL DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 81 NORTH AMERICA DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 82 NORTH AMERICA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 83 INCREMENTAL GROWTH IN NORTH AMERICA 2024 & 2030
EXHIBIT 84 US DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 85 CANADA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 86 EUROPE DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 87 EUROPE DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 88 INCREMENTAL GROWTH IN EUROPE 2024 & 2030
EXHIBIT 89 GERMANY DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 90 UK DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 91 FRANCE DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 92 ITALY DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 93 SPAIN DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 94 SWITZERLAND DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 95 NETHERLANDS DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 96 APAC DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 97 APAC DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 98 INCREMENTAL GROWTH IN APAC 2024 & 2030
EXHIBIT 99 CHINA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 100 JAPAN DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 101 INDIA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 102 SOUTH KOREA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 103 AUSTRALIA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 104 LATIN AMERICA DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 105 LATIN AMERICA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 106 INCREMENTAL GROWTH IN LATIN AMERICA 2024 & 2030
EXHIBIT 107 BRAZIL DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 108 MEXICO DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 109 ARGENTINA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 110 COLOMBIA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 111 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 112 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 113 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2024 & 2030
EXHIBIT 114 TURKEY DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 115 SOUTH AFRICA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 116 SAUDI ARABIA DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 117 UAE DNA DIAGNOSTICS MARKET 2021–2030 ($ BILLION)
EXHIBIT 118 VENDORS OFFERING DNA DIAGNOSTICS PRODUCTS: MARKET DOMINANCE ANALYSIS
EXHIBIT 119 VENDORS OFFERING COMMERCIAL DNA DIAGNOSTICS PRODUCTS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 120 KEY CAVEATS
LIST OF TABLES
TABLE 1 GLOBAL CONSUMABLES DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 2 GLOBAL CONSUMABLES DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 3 GLOBAL INSTRUMENTS & SOFTWARE DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 4 GLOBAL INSTRUMENTS & SOFTWARE DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 5 GLOBAL SERVICES DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 6 GLOBAL SERVICES DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 7 GLOBAL PCR DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 8 GLOBAL PCR DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 9 GLOBAL SEQUENCING DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 10 GLOBAL SEQUENCING DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 11 GLOBAL IN-SITU HYBRIDIZATION DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 12 GLOBAL IN-SITU HYBRIDIZATION DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 13 GLOBAL MICROARRAY DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 14 GLOBAL MICROARRAY DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 15 GLOBAL DNA FINGERPRINTING DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 16 GLOBAL DNA FINGERPRINTING DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 17 GLOBAL OTHER DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 18 GLOBAL OTHER DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 19 GLOBAL BLOOD, SERUM & PLASMA DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 20 GLOBAL BLOOD, SERUM & PLASMA DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 21 GLOBAL SALIVA DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 22 GLOBAL SALIVA DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 23 GLOBAL OTHERS DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 24 GLOBAL OTHERS DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 25 GLOBAL CANCER DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 26 GLOBAL CANCER DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 27 GLOBAL INFECTIOUS DISEASES DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 28 GLOBAL INFECTIOUS DISEASES DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 29 GLOBAL PRENATAL TESTING DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 30 GLOBAL PRENATAL TESTING DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 31 GLOBAL FORENSICS DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 32 GLOBAL FORENSICS DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 33 GLOBAL NEWBORN GENETIC SCREENING DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 34 GLOBAL NEWBORN GENETIC SCREENING DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 35 GLOBAL OTHER DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 36 GLOBAL OTHER DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 37 GLOBAL DIAGNOSTIC CENTERS DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 38 GLOBAL DIAGNOSTIC CENTERS DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 39 GLOBAL HOSPITALS & CLINICS DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 40 GLOBAL HOSPITALS & CLINICS DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 41 GLOBAL OTHER DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 42 GLOBAL OTHER DNA DIAGNOSTICS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 43 NORTH AMERICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 44 NORTH AMERICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 45 NORTH AMERICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 46 NORTH AMERICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 47 NORTH AMERICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 48 NORTH AMERICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 49 NORTH AMERICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 50 NORTH AMERICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 51 NORTH AMERICA DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 52 NORTH AMERICA DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 (%)
TABLE 53 EUROPE DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 54 EUROPE DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 55 EUROPE DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 56 EUROPE DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 57 EUROPE DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 58 EUROPE DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 59 EUROPE DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 60 EUROPE DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 61 EUROPE DNA DIAGNOSTICS MARKET BY END USER 2024−2030 ($ BILLION)
TABLE 62 EUROPE DNA DIAGNOSTICS MARKET BY END USER 2024−2030 (%)
TABLE 63 APAC DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 64 APAC DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 65 APAC DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 66 APAC DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 67 APAC DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 68 APAC DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 69 APAC DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 70 APAC DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 71 APAC DNA DIAGNOSTICS MARKET BY END USER 2024−2030 ($ BILLION)
TABLE 72 APAC DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 (%)
TABLE 73 LATIN AMERICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 74 LATIN AMERICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 75 LATIN AMERICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 76 LATIN AMERICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 77 LATIN AMERICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 78 LATIN AMERICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 79 LATIN AMERICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 80 LATIN AMERICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 81 LATIN AMERICA DNA DIAGNOSTICS MARKET BY END USER 2024−2030 ($ BILLION)
TABLE 82 LATIN AMERICA DNA DIAGNOSTICS MARKET BY END USER 2024−2030 (%)
TABLE 83 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 84 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 85 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 86 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 87 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 88 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 89 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 90 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 91 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY END USER 2024−2030 ($ BILLION)
TABLE 92 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY END USER 2024−2030 (%)
TABLE 93 ANALYSIS OF KEY MARKET PLAYERS
TABLE 94 ABBOTT: MAJOR PRODUCT OFFERINGS
TABLE 95 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 96 ILLUMINA: MAJOR PRODUCT OFFERINGS
TABLE 97 QAIGEN: MAJOR PRODUCT OFFERINGS
TABLE 98 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 99 23ANDME: MAJOR PRODUCT OFFERINGS
TABLE 100 24GENETICS: MAJOR PRODUCT OFFERINGS
TABLE 101 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 102 ANCESTRY: MAJOR PRODUCT OFFERINGS
TABLE 103 BEYOND NUTRITION HEALTH AND WELLNESS SERVICES DMCC: MAJOR PRODUCT OFFERINGS
TABLE 104 BILLIONTOONE: MAJOR PRODUCT OFFERINGS
TABLE 105 CIRCLEDNA: MAJOR PRODUCT OFFERINGS
TABLE 106 DANAHER: MAJOR PRODUCT OFFERINGS
TABLE 107 EVERLYWELL: MAJOR PRODUCT OFFERINGS
TABLE 108 GE HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 109 GENEDX: MAJOR PRODUCT OFFERINGS
TABLE 110 GENETRACK INDIA: MAJOR PRODUCT OFFERINGS
TABLE 111 HELIX: MAJOR PRODUCT OFFERINGS
TABLE 112 IGENOMIX: MAJOR PRODUCT OFFERINGS
TABLE 113 MAINZ BIOMED N.V.: MAJOR PRODUCT OFFERINGS
TABLE 114 MAPMYGENOME: MAJOR PRODUCT OFFERINGS
TABLE 115 MERCK KGAA: MAJOR PRODUCT OFFERINGS
TABLE 116 MYDNA LIFE AUSTRALIA: MAJOR PRODUCT OFFERINGS
TABLE 117 MYHERITAGE: MAJOR PRODUCT OFFERINGS
TABLE 118 NATERA: MAJOR PRODUCT OFFERINGS
TABLE 119 TELLMEGEN: MAJOR PRODUCT OFFERINGS
TABLE 120 VITAGEN-X PRECISION NUTRITION: MAJOR PRODUCT OFFERINGS
TABLE 121 GLOBAL DNA DIAGNOSTICS MARKET BY PRODUCT 2024−2030 ($ BILLION)
TABLE 122 GLOBAL DNA DIAGNOSTICS MARKET BY PRODUCT 2024−2030 (%)
TABLE 123 NORTH AMERICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 124 NORTH AMERICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 125 EUROPE DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 126 EUROPE DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 127 APAC DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 128 APAC DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 129 LATIN AMERICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 130 LATIN AMERICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 131 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 ($ BILLION)
TABLE 132 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY PRODUCT TYPE 2024−2030 (%)
TABLE 133 GLOBAL DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 134 GLOBAL DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 135 NORTH AMERICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 136 NORTH AMERICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 137 EUROPE DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 138 EUROPE DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 139 APAC DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 140 APAC DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 141 LATIN AMERICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 142 LATIN AMERICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 143 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 144 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 145 GLOBAL DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 146 GLOBAL DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 147 NORTH AMERICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 148 NORTH AMERICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 149 EUROPE DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 150 EUROPE DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 151 APAC DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 152 APAC DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 153 LATIN AMERICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 154 LATIN AMERICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 155 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 ($ BILLION)
TABLE 156 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY SAMPLE TYPE 2024−2030 (%)
TABLE 157 GLOBAL DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 158 GLOBAL DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 159 NORTH AMERICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 160 NORTH AMERICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 161 EUROPE DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 162 EUROPE DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 163 APAC DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 164 APAC DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 165 LATIN AMERICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 166 LATIN AMERICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 167 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 168 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY APPLICATION 2024−2030 (%)
TABLE 169 GLOBAL DNA DIAGNOSTICS MARKET BY END USER 2024−2030 ($ BILLION)
TABLE 170 GLOBAL DNA DIAGNOSTICS MARKET BY END USER 2024−2030 (%)
TABLE 171 NORTH AMERICA DNA DIAGNOSTICS MARKET BY END USER 2024−2030 ($ BILLION)
TABLE 172 NORTH AMERICA DNA DIAGNOSTICS MARKET BY END USER 2024−2030 (%)
TABLE 173 EUROPE DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 174 EUROPE DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 (%)
TABLE 175 APAC DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 176 APAC DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 (%)
TABLE 177 LATIN AMERICA DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 178 LATIN AMERICA DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 (%)
TABLE 179 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 180 MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET BY END-USER 2024−2030 (%)
TABLE 181 CURRENCY CONVERSION 2018−2024
1. SCOPE & COVERAGE
1.1. MARKET DEFINITION
1.1.1. INCLUSIONS
1.1.2. EXCLUSIONS
1.1.3. MARKET ESTIMATION CAVEATS
1.2. MARKET SEGMENT COVERAGE & DEFINITION
1.2.1. PRODUCT TYPE
1.2.2. TECHNOLOGY
1.2.3. SAMPLE TYPE
1.2.4. APPLICATION
1.2.5. END-USER
1.2.6. REGIONS & COUNTRIES COVERED
1.3. MARKET DERIVATION
BASE YEAR
2. PREMIUM INSIGHTS
2.1. OPPORTUNITY POCKETS
2.2. OVERVIEW
3. MARKET AT A GLANCE
4. INTRODUCTION
4.1. OVERVIEW
5. MARKET OPPORTUNITIES & TRENDS
5.1. EMERGENCE OF LIQUID BIOPSY
5.2. INCREASE IN DIRECT-TO-CONSUMER (DTC) TESTING
5.3. TRANSITION FROM CLASSICAL TO SMART BIOINFORMATICS
5.4. ADVANCEMENTS IN GENOMICS AND PERSONALIZED MEDICINE
6. MARKET GROWTH ENABLERS
6.1. INCREASING PREVALENCE OF GENETIC AND CHRONIC DISORDERS
6.2. TECHNOLOGICAL ADVANCEMENTS IN DNA SEQUENCING
6.3. EXPANDING APPLICATIONS OF DNA DIAGNOSTICS
6.4. RISING AWARENESS OF EARLY DISEASE DETECTION
7. MARKET RESTRAINTS
7.1. AVAILABILITY OF ALTERNATE DISEASE DIAGNOSTIC & DETECTION METHODS
7.2. ETHICAL AND PRIVACY CONCERNS
7.3. COMPLEX REGULATORY FRAMEWORKS
8. MARKET LANDSCAPE
8.1. MARKET OVERVIEW
8.2. MARKET SIZE & FORECAST
8.3. FIVE FORCES ANALYSIS
8.3.1. THREAT OF NEW ENTRANTS
8.3.2. BARGAINING POWER OF SUPPLIERS
8.3.3. BARGAINING POWER OF BUYERS
8.3.4. THREAT OF SUBSTITUTES
8.3.5. COMPETITIVE RIVALRY
9. PRODUCT TYPE
9.1. MARKET SNAPSHOT & GROWTH ENGINE
9.2. MARKET OVERVIEW
9.3. CONSUMABLES
9.3.1. MARKET OVERVIEW
9.3.2. MARKET SIZE & FORECAST
9.3.3. MARKET BY GEOGRAPHY
9.4. INSTRUMENTS & SOFTWARE
9.4.1. MARKET OVERVIEW
9.4.2. MARKET SIZE & FORECAST
9.4.3. MARKET BY GEOGRAPHY
9.5. SERVICES
9.5.1. MARKET OVERVIEW
9.5.2. MARKET SIZE & FORECAST
9.5.3. MARKET BY GEOGRAPHY
10. TECHNOLOGY
10.1. MARKET SNAPSHOT & GROWTH ENGINE
10.2. MARKET OVERVIEW
10.3. POLYMERASE CHAIN REACTION (PCR)
10.3.1. MARKET OVERVIEW
10.3.2. MARKET SIZE & FORECAST
10.3.3. MARKET BY GEOGRAPHY
10.4. SEQUENCING
10.4.1. MARKET OVERVIEW
10.4.2. MARKET SIZE & FORECAST
10.4.3. MARKET BY GEOGRAPHY
10.5. IN-SITU HYBRIDIZATION (ISH)
10.5.1. MARKET OVERVIEW
10.5.2. MARKET SIZE & FORECAST
10.5.3. MARKET BY GEOGRAPHY
10.6. MICROARRAY
10.6.1. MARKET OVERVIEW
10.6.2. MARKET SIZE & FORECAST
10.6.3. MARKET BY GEOGRAPHY
10.7. DNA FINGERPRINTING
10.7.1. MARKET OVERVIEW
10.7.2. MARKET SIZE & FORECAST
10.7.3. MARKET BY GEOGRAPHY
10.8. OTHERS
10.8.1. MARKET OVERVIEW
10.8.2. MARKET SIZE & FORECAST
10.8.3. MARKET BY GEOGRAPHY
11. SAMPLE TYPE
11.1. MARKET SNAPSHOT & GROWTH ENGINE
11.2. MARKET OVERVIEW
11.3. BLOOD, SERUM & PLASMA
11.3.1. MARKET OVERVIEW
11.3.2. MARKET SIZE & FORECAST
11.3.3. MARKET BY GEOGRAPHY
11.4. SALIVA
11.4.1. MARKET OVERVIEW
11.4.2. MARKET SIZE & FORECAST
11.4.3. MARKET BY GEOGRAPHY
11.5. OTHERS
11.5.1. MARKET OVERVIEW
11.5.2. MARKET SIZE & FORECAST
11.5.3. MARKET BY GEOGRAPHY
12. APPLICATION
12.1. MARKET SNAPSHOT & GROWTH ENGINE
12.2. MARKET OVERVIEW
12.3. CANCER
12.3.1. MARKET OVERVIEW
12.3.2. MARKET SIZE & FORECAST
12.3.3. MARKET BY GEOGRAPHY
12.4. INFECTIOUS DISEASES
12.4.1. MARKET OVERVIEW
12.4.2. MARKET SIZE & FORECAST
12.4.3. MARKET BY GEOGRAPHY
12.5. PRENATAL TESTING
12.5.1. MARKET OVERVIEW
12.5.2. MARKET SIZE & FORECAST
12.5.3. MARKET BY GEOGRAPHY
12.6. FORENSICS
12.6.1. MARKET OVERVIEW
12.6.2. MARKET SIZE & FORECAST
12.6.3. MARKET BY GEOGRAPHY
12.7. NEWBORN GENETIC SCREENING
12.7.1. MARKET OVERVIEW
12.7.2. MARKET SIZE & FORECAST
12.7.3. MARKET BY GEOGRAPHY
12.8. OTHERS
12.8.1. MARKET OVERVIEW
12.8.2. MARKET SIZE & FORECAST
12.8.3. MARKET BY GEOGRAPHY
13. END USER
13.1. MARKET SNAPSHOT & GROWTH ENGINE
13.2. MARKET OVERVIEW
13.3. DIAGNOSTIC CENTERS
13.3.1. MARKET OVERVIEW
13.3.2. MARKET SIZE & FORECAST
13.3.3. MARKET BY GEOGRAPHY
13.4. HOSPITALS & CLINICS
13.4.1. MARKET OVERVIEW
13.4.2. MARKET SIZE & FORECAST
13.4.3. MARKET BY GEOGRAPHY
13.5. OTHERS
13.5.1. MARKET OVERVIEW
13.5.2. MARKET SIZE & FORECAST
13.5.3. MARKET BY GEOGRAPHY
14. GEOGRAPHY
14.1. MARKET SNAPSHOT & GROWTH ENGINE
14.2. GEOGRAPHIC OVERVIEW
15. NORTH AMERICA
15.1. MARKET OVERVIEW
15.2. MARKET SIZE & FORECAST
15.2.1. PRODUCT TYPE
15.2.2. TECHNOLOGY
15.2.3. SAMPLE TYPE
15.2.4. APPLICATION
15.2.5. END-USER
15.3. KEY COUNTRIES
15.3.1. US: MARKET SIZE & FORECAST
15.3.2. CANADA: MARKET SIZE & FORECAST
16. EUROPE
16.1. MARKET OVERVIEW
16.2. MARKET SIZE & FORECAST
16.2.1. PRODUCT TYPE
16.2.2. TECHNOLOGY
16.2.3. SAMPLE TYPE
16.2.4. APPLICATION
16.2.5. END USER
16.3. KEY COUNTRIES
16.3.1. GERMANY: MARKET SIZE & FORECAST
16.3.2. UK: MARKET SIZE & FORECAST
16.3.3. FRANCE: MARKET SIZE & FORECAST
16.3.4. ITALY: MARKET SIZE & FORECAST
16.3.5. SPAIN: MARKET SIZE & FORECAST
16.3.6. SWITZERLAND: MARKET SIZE & FORECAST
16.3.7. NETHERLANDS: MARKET SIZE & FORECAST
17. APAC
17.1. MARKET OVERVIEW
17.2. MARKET SIZE & FORECAST
17.2.1. PRODUCT TYPE
17.2.2. TECHNOLOGY
17.2.3. SAMPLE TYPE
17.2.4. APPLICATION
17.2.5. END USER
17.3. KEY COUNTRIES
17.3.1. CHINA: MARKET SIZE & FORECAST
17.3.2. JAPAN: MARKET SIZE & FORECAST
17.3.3. INDIA: MARKET SIZE & FORECAST
17.3.4. SOUTH KOREA: MARKET SIZE & FORECAST
17.3.5. AUSTRALIA: MARKET SIZE & FORECAST
18. LATIN AMERICA
18.1. MARKET OVERVIEW
18.2. MARKET SIZE & FORECAST
18.2.1. PRODUCT TYPE
18.2.2. TECHNOLOGY
18.2.3. SAMPLE TYPE
18.2.4. APPLICATION
18.2.5. END USER
18.3. KEY COUNTRIES
18.3.1. BRAZIL: MARKET SIZE & FORECAST
18.3.2. MEXICO: MARKET SIZE & FORECAST
18.3.3. ARGENTINA: MARKET SIZE & FORECAST
18.3.4. COLOMBIA: MARKET SIZE & FORECAST
19. MIDDLE EAST & AFRICA
19.1. MARKET OVERVIEW
19.2. MARKET SIZE & FORECAST
19.2.1. PRODUCT TYPE
19.2.2. TECHNOLOGY
19.2.3. SAMPLE TYPE
19.2.4. APPLICATION
19.2.5. END USER
19.3. KEY COUNTRIES
19.3.1. TURKEY: MARKET SIZE & FORECAST
19.3.2. SOUTH AFRICA: MARKET SIZE & FORECAST
19.3.3. SAUDI ARABIA: MARKET SIZE & FORECAST
19.3.4. UAE: MARKET SIZE & FORECAST
20. COMPETITIVE LANDSCAPE
20.1. COMPETITION OVERVIEW
20.2. MARKET SHARE ANALYSIS
20.2.1. ABBOTT
20.2.2. F. HOFFMANN-LA ROCHE
20.2.3. ILLUMINA
20.2.4. QAIGEN
20.2.5. THERMO FISHER SCIENTIFIC
21. KEY COMPANY PROFILES
21.1. ABBOTT
21.1.1. BUSINESS OVERVIEW
21.1.2. PRODUCT OFFERINGS
21.1.3. KEY STRATEGIES
21.1.4. KEY STRENGTHS
21.1.5. KEY OPPORTUNITIES
21.2. F. HOFFMANN-LA ROCHE
21.2.1. BUSINESS OVERVIEW
21.2.2. PRODUCT OFFERINGS
21.2.3. KEY STRATEGIES
21.2.4. KEY STRENGTHS
21.2.5. KEY OPPORTUNITIES
21.3. ILLUMINA
21.3.1. BUSINESS OVERVIEW
21.3.2. PRODUCT OFFERINGS
21.3.3. KEY STRATEGIES
21.3.4. KEY STRENGTHS
21.3.5. KEY OPPORTUNITIES
21.4. QAIGEN
21.4.1. BUSINESS OVERVIEW
21.4.2. PRODUCT OFFERINGS
21.4.3. KEY STRATEGIES
21.4.4. KEY STRENGTHS
21.4.5. KEY OPPORTUNITIES
21.5. THERMO FISHER SCIENTIFIC
21.5.1. BUSINESS OVERVIEW
21.5.2. PRODUCT OFFERINGS
21.5.3. KEY STRATEGIES
21.5.4. KEY STRENGTHS
21.5.5. KEY OPPORTUNITIES
22. OTHER PROMINENT VENDORS
22.1. 23ANDME
22.1.1. BUSINESS OVERVIEW
22.1.2. PRODUCT OFFERINGS
22.2. 24GENETICS
22.2.1. BUSINESS OVERVIEW
22.2.2. PRODUCT OFFERINGS
22.3. AGILENT TECHNOLOGIES
22.3.1. BUSINESS OVERVIEW
22.3.2. PRODUCT OFFERINGS
22.4. ANCESTRY
22.4.1. BUSINESS OVERVIEW
22.4.2. PRODUCT OFFERINGS
22.5. BEYOND NUTRITION HEALTH AND WELLNESS SERVICES DMCC
22.5.1. BUSINESS OVERVIEW
22.5.2. PRODUCT OFFERINGS
22.6. BILLIONTOONE
22.6.1. BUSINESS OVERVIEW
22.6.2. PRODUCT OFFERINGS
22.7. CIRCLE DNA
22.7.1. BUSINESS OVERVIEW
22.7.2. PRODUCT OFFERINGS
22.8. DANAHER
22.8.1. BUSINESS OVERVIEW
22.8.2. PRODUCT OFFERINGS
22.9. EVERLYWELL
22.9.1. BUSINESS OVERVIEW
22.9.2. PRODUCT OFFERINGS
22.10. GE HEALTHCARE
22.10.1. BUSINESS OVERVIEW
22.10.2. PRODUCT OFFERINGS
22.11. GENEDX
22.11.1. BUSINESS OVERVIEW
22.11.2. PRODUCT OFFERINGS
22.12. GENETRACK INDIA
22.12.1. BUSINESS OVERVIEW
22.12.2. PRODUCT OFFERINGS
22.13. HELIX
22.13.1. BUSINESS OVERVIEW
22.13.2. PRODUCT OFFERINGS
22.14. IGENOMIX
22.14.1. BUSINESS OVERVIEW
22.14.2. PRODUCT OFFERINGS
22.15. MAINZ BIOMED N.V.
22.15.1. BUSINESS OVERVIEW
22.15.2. PRODUCT OFFERINGS
22.16. MAPMYGENOME
22.16.1. BUSINESS OVERVIEW
22.16.2. PRODUCT OFFERINGS
22.17. MERCK KGAA
22.17.1. BUSINESS OVERVIEW
22.17.2. PRODUCT OFFERINGS
22.18. MYDNA LIFE AUSTRALIA
22.18.1. BUSINESS OVERVIEW
22.18.2. PRODUCT OFFERINGS
22.19. MYHERITAGE
22.19.1. BUSINESS OVERVIEW
22.19.2. PRODUCT OFFERINGS
22.20. NATERA
22.20.1. BUSINESS OVERVIEW
22.20.2. PRODUCT OFFERINGS
22.21. TELLMEGEN
22.21.1. BUSINESS OVERVIEW
22.21.2. PRODUCT OFFERINGS
22.22. VITAGEN-X PRECISION NUTRITION
22.22.1. BUSINESS OVERVIEW
22.22.2. PRODUCT OFFERINGS
23. REPORT SUMMARY
23.1. KEY TAKEAWAYS
23.2. STRATEGIC RECOMMENDATIONS
24. QUANTITATIVE SUMMARY
24.1. MARKET BY PRODUCT TYPE
24.1.1. NORTH AMERICA
24.1.2. EUROPE
24.1.3. APAC
24.1.4. LATIN AMERICA
24.1.5. MIDDLE EAST & AFRICA
24.2. MARKET BY TECHNOLOGY
24.2.1. NORTH AMERICA
24.2.2. EUROPE
24.2.3. APAC
24.2.4. LATIN AMERICA
24.2.5. MIDDLE EAST & AFRICA
24.3. MARKET BY SAMPLE TYPE
24.3.1. NORTH AMERICA
24.3.2. EUROPE
24.3.3. APAC
24.3.4. LATIN AMERICA
24.3.5. MIDDLE EAST & AFRICA
24.4. MARKET BY APPLICATION
24.4.1. NORTH AMERICA
24.4.2. EUROPE
24.4.3. APAC
24.4.4. LATIN AMERICA
24.4.5. MIDDLE EAST & AFRICA
24.5. MARKET BY END USER
24.5.1. NORTH AMERICA
24.5.3. EUROPE
24.5.5. APAC
24.5.7. LATIN AMERICA
24.5.8. MIDDLE EAST & AFRICA
25. APPENDIX
25.1. RESEARCH METHODOLOGY
25.2. RESEARCH PROCESS
25.3. REPORT ASSUMPTIONS & CAVEATS
25.3.1. KEY CAVEATS
25.3.2. CURRENCY CONVERSION
25.4. ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the global DNA diagnostics market?
What is the growth rate of the global DNA diagnostics market?
Which region dominates the global DNA diagnostics market share?
What are the significant trends in the DNA diagnostics industry?
Who are the key players in the global DNA diagnostics market?
Other RELATED Reports
In Vitro Diagnostics Market - Global Outlook & Forecast 2023-2028
Published : February 2023